Psoriatic Arthritis Therapeutics Market: Global Industry Analysis and Forecast (2022-2029)


Psoriatic Arthritis Therapeutics Market size is expected to reach US$ 15.74 Bn. by year 2029 at a CAGR of 9.5% during the forecast period.

Psoriatic arthritis is a form of arthritis that affects several peoples who have psoriasis. Psoriatic arthritis is an autoimmune disorder that primarily affects psoriasis patients, with nearly 30% of the patient population at risk.

Psoriatic Arthritis Therapeutics Market

To know about the Research Methodology :- Request Free Sample Report

The psoriatic arthritis therapeutics market is primarily driven by a growth in the prevalence of psoriatic arthritis, novel product development and rise in adoption of biologics for the treatment of moderate to simple psoriatic arthritis with unmet medical needs across the globe. Moreover, rising awareness of approximately psoriatic arthritis treatment between the healthcare authorities and developing the elderly population.

Psoriatic Arthritis Therapeutics Market Dynamics:

However, the high cost of the drugs and treatment, and lack of modification tools for diagnosis and procedure are the major restraints in the market. Psoriatic arthritis is an autoimmune disorder, which is temporary as an obstacle for the development of a potential medicine for the suggestion and high treatment costs are challenges in the psoriatic arthritis therapeutics market.

Based on the drug class, the Nonsteroidal anti-inflammatory drug (NSAID) segment is held to dominate the xx% market share during the forecast period. Nonsteroidal anti-inflammatory causes are a collection of medicines that relieve pain and fever and reduce inflammation. NSAIDs are usually the main treatment, NSAIDs are also generally used as an assistant treatment in conjunction with biologics otherwise disease-modifying antirheumatic drugs (DMAD).

The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis.

The topical segment expected to dominate the xx% market share during the forecast period, owing to the occurrence of improved substitutes with more effective mechanisms of accomplishment. The topical segment normalizes excessive cell reproduction and decreases inflammation caused in psoriasis. There are some effective topical treatments for psoriasis, while many can be procured over the counter (OTC).

Psoriatic Arthritis Therapeutics Market Regional Insights:

Regionally, North America is expected to account for the largest share of the psoriatic arthritis therapeutics market during the forecast period. Owing to increased awareness and growing prevalence of psoriatic arthritis. North America largely is driven by the commercial contracts of products in the United States. Furthermore, the presence of significant establishments, proactive government initiatives, favorable reimbursement policies, and a large patient pool support the psoriatic arthritis treatment market.

The report covers the recent development in the psoriatic arthritis therapeutics market i.e., in November 2018, AbbVie declared patent authorization agreements with Pfizer over its proposed biosimilar adalimumab product. In the terms of the contracts, AbbVie will contribution Pfizer a non-exclusive authorization on specified periods to AbbVie's intelligent assets relating to HUMIRA in the United States and in various other states around the creation in which AbbVie has intellectual assets.

The objective of the report is to present comprehensive analysis of global psoriatic arthritis therapeutics market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers the all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region.

PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers.

The report also helps in understanding global psoriatic arthritis therapeutics market dynamics, structure by analyzing the market segments, and project the global Psoriatic Arthritis Therapeutics market size. Clear representation of competitive analysis of key players by type, price, financial position, product portfolio, growth strategies, and regional presence in the global psoriatic arthritis therapeutics market make the report investor’s guide.

Psoriatic Arthritis Therapeutics Market Scope: Inquire before buying


Psoriatic Arthritis Therapeutics Market, by Drug Class

• Nonsteroidal anti-inflammatory drug (NSAID)
• Disease-modifying antirheumatic drug (DMARD)
• Biologic drug
• Enzyme inhibitor
• Interleukin Inhibitors
• Others

Psoriatic Arthritis Therapeutics Market, by Disease Type

• Asymmetric Psoriatic Arthritis
• Symmetric Psoriatic Arthritis
• Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis
• Spondylitis
• Arthritis Mutilans

Psoriatic Arthritis Therapeutics Market, by Distribution Channe

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

Psoriatic Arthritis Therapeutics Market, by Route of Administration

• Topical
• Oral
• Injectable

Psoriatic Arthritis Therapeutics Market, by Region

• North America
• Europe
• Asia Pacific
• Middle East & Africa
• South America

Psoriatic Arthritis Therapeutics Market, Key Players

• Pfizer Inc
• Eisai Inc
• UCB Biosciences Inc
• Sanofi
• Otsuka Pharmaceutical
• Sumitomo Dainippon Pharma Co
• Johnson & Johnson
• Celgene Corporation
• AbbVie Inc.
• Novartis AG
• Janssen Biotech
• Eli Lilly and Company
• Biogen Inc.
• Bristol-Myers Squibb Company
• Abbott Laboratories
• Amgen Inc.
• AstraZeneca
• Merck & Co

Frequently Asked Questions:

1. Which region has the largest share in Global Psoriatic Arthritis Therapeutics Market?
Ans: North America region holds the highest share in 2021.

2. What is the growth rate of Global Psoriatic Arthritis Therapeutics Market?
Ans: The Global Psoriatic Arthritis Therapeutics Market is growing at a CAGR of 9.5% during forecasting period 2022-2029.

3. What is scope of the Global Psoriatic Arthritis Therapeutics market report?
Ans: Global Psoriatic Arthritis Therapeutics Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.

4. Who are the key players in Global Psoriatic Arthritis Therapeutics market?
Ans: The important key players in the Global Psoriatic Arthritis Therapeutics Market are – Pfizer Inc, Eisai Inc, UCB Biosciences Inc, Sanofi, Otsuka Pharmaceutical, Sumitomo Dainippon Pharma Co, Johnson & Johnson, Celgene Corporation, AbbVie Inc., Novartis AG, Janssen Biotech, Eli Lilly and Company, Biogen Inc., Bristol-Myers Squibb Company, Abbott Laboratories, Amgen Inc., AstraZeneca, and Merck & Co

5. What is the study period of this market?
Ans: The Global Psoriatic Arthritis Therapeutics Market is studied from 2021 to 2029. 




Global Psoriatic Arthritis Therapeutics Market

1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
1.3. Research Objectives

2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Abbreviations
2.3. Research Methodology
2.3.1. Secondary Research
2.3.1.1. Secondary data
2.3.1.2. Secondary Sources
2.3.2. Primary Research
2.3.2.1. Data from Primary Sources
2.3.2.2. Breakdown of Primary Sources

3. Executive Summary: Global Psoriatic Arthritis Therapeutics Market Size, by Market Value (US$ Bn)

4. Market Overview
4.1. Introduction
4.2. Market Indicator
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Porter’s Analysis
4.4. Value Chain Analysis
4.5. Market Risk Analysis
4.6. SWOT Analysis
4.7. Industry Trends and Emerging Technologies

5. Supply Side and Demand Side Indicators
6. Global Psoriatic Arthritis Therapeutics Market Analysis and Forecast
6.1. Global Psoriatic Arthritis Therapeutics Market Size & Y-o-Y Growth Analysis
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Middle East & Africa
6.1.5. South America

7. Global Psoriatic Arthritis Therapeutics Market Analysis and Forecast, by Drug Class
7.1. Introduction and Definition
7.2. Key Findings
7.3. Global Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Drug Class
7.4. Global Psoriatic Arthritis Therapeutics Market Size (US$ Bn) Forecast, by Drug Class
7.5. Global Psoriatic Arthritis Therapeutics Market Analysis, by Drug Class
7.6. Global Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Drug Class

8. Global Psoriatic Arthritis Therapeutics Market Analysis and Forecast, by Disease Type
8.1. Introduction and Definition
8.2. Key Findings
8.3. Global Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Disease Type
8.4. Global Psoriatic Arthritis Therapeutics Market Size (US$ Bn) Forecast, by Disease Type
8.5. Global Psoriatic Arthritis Therapeutics Market Analysis, by Disease Type
8.6. Global Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Disease Type

9. Global Psoriatic Arthritis Therapeutics Market Analysis and Forecast, by Distribution Channel
9.1. Introduction and Definition
9.2. Key Findings
9.3. Global Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Distribution Channel
9.4. Global Psoriatic Arthritis Therapeutics Market Size (US$ Bn) Forecast, by Distribution Channel
9.5. Global Psoriatic Arthritis Therapeutics Market Analysis, by Distribution Channel
9.6. Global Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Distribution Channel

10. Global Psoriatic Arthritis Therapeutics Market Analysis and Forecast, by Route of Administration
10.1. Introduction and Definition
10.2. Key Findings
10.3. Global Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Route of Administration
10.4. Global Psoriatic Arthritis Therapeutics Market Size (US$ Bn) Forecast, by Route of Administration
10.5. Global Psoriatic Arthritis Therapeutics Market Analysis, by Route of Administration
10.6. Global Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Route of Administration

11. Global Psoriatic Arthritis Therapeutics Market Analysis, by Region
11.1. Global Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Region
11.2. Global Psoriatic Arthritis Therapeutics Market Size (US$ Bn) Forecast, by Region
11.3. Global Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Region

12. North America Psoriatic Arthritis Therapeutics Market Analysis
12.1. Key Findings
12.2. North America Psoriatic Arthritis Therapeutics Market Overview
12.3. North America Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Drug Class
12.4. North America Psoriatic Arthritis Therapeutics Market Forecast, by Drug Class
12.4.1. Nonsteroidal anti-inflammatory drug (NSAID)
12.4.2. Disease-modifying antirheumatic drug (DMARD)
12.4.3. Biologic drug
12.4.4. Enzyme inhibitor
12.4.5. Interleukin Inhibitors
12.4.6. Others
12.5. North America Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Disease Type
12.6. North America Psoriatic Arthritis Therapeutics Market Forecast, by Disease Type
12.6.1. Asymmetric Psoriatic Arthritis
12.6.2. Symmetric Psoriatic Arthritis
12.6.3. Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis
12.6.4. Spondylitis
12.6.5. Arthritis Mutilans
12.7. North America Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Distribution Channel
12.8. North America Psoriatic Arthritis Therapeutics Market Forecast, by Distribution Channel
12.8.1. Hospital Pharmacies
12.8.2. Online Pharmacies
12.8.3. Retail Pharmacies
12.9. North America Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Route of Administration
12.10. North America Psoriatic Arthritis Therapeutics Market Forecast, by Route of Administration
12.10.1. Topical
12.10.2. Oral
12.10.3. Injectable
12.11. North America Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Country
12.12. North America Psoriatic Arthritis Therapeutics Market Forecast, by Country
12.12.1. U.S.
12.12.2. Canada
12.13. North America Psoriatic Arthritis Therapeutics Market Analysis, by Country
12.14. U.S. Psoriatic Arthritis Therapeutics Market Forecast, by Drug Class
12.14.1. Nonsteroidal anti-inflammatory drug (NSAID)
12.14.2. Disease-modifying antirheumatic drug (DMARD)
12.14.3. Biologic drug
12.14.4. Enzyme inhibitor
12.14.5. Interleukin Inhibitors
12.14.6. Others
12.15. U.S. Psoriatic Arthritis Therapeutics Market Forecast, by Disease Type
12.15.1. Asymmetric Psoriatic Arthritis
12.15.2. Symmetric Psoriatic Arthritis
12.15.3. Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis
12.15.4. Spondylitis
12.15.5. Arthritis Mutilans
12.16. U.S. Psoriatic Arthritis Therapeutics Market Forecast, by Distribution Channel
12.16.1. Hospital Pharmacies
12.16.2. Online Pharmacies
12.16.3. Retail Pharmacies
12.17. U.S. Psoriatic Arthritis Therapeutics Market Forecast, by Route of Administration
12.17.1. Topical
12.17.2. Oral
12.17.3. Injectable
12.18. Canada Psoriatic Arthritis Therapeutics Market Forecast, by Drug Class
12.18.1. Nonsteroidal anti-inflammatory drug (NSAID)
12.18.2. Disease-modifying antirheumatic drug (DMARD)
12.18.3. Biologic drug
12.18.4. Enzyme inhibitor
12.18.5. Interleukin Inhibitors
12.18.6. Others
12.19. Canada Psoriatic Arthritis Therapeutics Market Forecast, by Disease Type
12.19.1. Asymmetric Psoriatic Arthritis
12.19.2. Symmetric Psoriatic Arthritis
12.19.3. Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis
12.19.4. Spondylitis
12.19.5. Arthritis Mutilans
12.20. Canada Psoriatic Arthritis Therapeutics Market Forecast, by Distribution Channel
12.20.1. Hospital Pharmacies
12.20.2. Online Pharmacies
12.20.3. Retail Pharmacies
12.21. Canada Psoriatic Arthritis Therapeutics Market Forecast, by Route of Administration
12.21.1. Topical
12.21.2. Oral
12.21.3. Injectable
12.22. North America Psoriatic Arthritis Therapeutics Market Attractiveness Analysis
12.22.1. By Drug Class
12.22.2. By Disease Type
12.22.3. By Distribution Channel
12.22.4. By Route of Administration
12.23. PEST Analysis
12.24. Key Trends
12.25. Key Developments

13. Europe Psoriatic Arthritis Therapeutics Market Analysis
13.1. Key Findings
13.2. Europe Psoriatic Arthritis Therapeutics Market Overview
13.3. Europe Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Drug Class
13.4. Europe Psoriatic Arthritis Therapeutics Market Forecast, by Drug Class
13.4.1. Nonsteroidal anti-inflammatory drug (NSAID)
13.4.2. Disease-modifying antirheumatic drug (DMARD)
13.4.3. Biologic drug
13.4.4. Enzyme inhibitor
13.4.5. Interleukin Inhibitors
13.4.6. Others
13.5. Europe Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Disease Type
13.6. Europe Psoriatic Arthritis Therapeutics Market Forecast, by Disease Type
13.6.1. Asymmetric Psoriatic Arthritis
13.6.2. Symmetric Psoriatic Arthritis
13.6.3. Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis
13.6.4. Spondylitis
13.6.5. Arthritis Mutilans
13.7. Europe Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Distribution Channel
13.8. Europe Psoriatic Arthritis Therapeutics Market Forecast, by Distribution Channel
13.8.1. Hospital Pharmacies
13.8.2. Online Pharmacies
13.8.3. Retail Pharmacies
13.9. Europe Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Route of Administration
13.10. Europe Psoriatic Arthritis Therapeutics Market Forecast, by Route of Administration
13.10.1. Topical
13.10.2. Oral
13.10.3. Injectable
13.11. Europe Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Country
13.12. Europe Psoriatic Arthritis Therapeutics Market Forecast, by Country
13.12.1. Germany
13.12.2. U.K.
13.12.3. France
13.12.4. Italy
13.12.5. Spain
13.12.6. Rest of Europe
13.13. Europe Psoriatic Arthritis Therapeutics Market Analysis, by Country
13.14. Germany Psoriatic Arthritis Therapeutics Market Forecast, by Drug Class
13.14.1. Nonsteroidal anti-inflammatory drug (NSAID)
13.14.2. Disease-modifying antirheumatic drug (DMARD)
13.14.3. Biologic drug
13.14.4. Enzyme inhibitor
13.14.5. Interleukin Inhibitors
13.14.6. Others
13.15. Germany Psoriatic Arthritis Therapeutics Market Forecast, by Disease Type
13.15.1. Asymmetric Psoriatic Arthritis
13.15.2. Symmetric Psoriatic Arthritis
13.15.3. Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis
13.15.4. Spondylitis
13.15.5. Arthritis Mutilans
13.16. Germany Psoriatic Arthritis Therapeutics Market Forecast, by Distribution Channel
13.16.1. Hospital Pharmacies
13.16.2. Online Pharmacies
13.16.3. Retail Pharmacies
13.17. Germany Psoriatic Arthritis Therapeutics Market Forecast, by Route of Administration
13.17.1. Topical
13.17.2. Oral
13.17.3. Injectable
13.18. U.K. Psoriatic Arthritis Therapeutics Market Forecast, by Drug Class
13.18.1. Nonsteroidal anti-inflammatory drug (NSAID)
13.18.2. Disease-modifying antirheumatic drug (DMARD)
13.18.3. Biologic drug
13.18.4. Enzyme inhibitor
13.18.5. Interleukin Inhibitors
13.18.6. Others
13.19. U.K. Psoriatic Arthritis Therapeutics Market Forecast, by Disease Type
13.19.1. Asymmetric Psoriatic Arthritis
13.19.2. Symmetric Psoriatic Arthritis
13.19.3. Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis
13.19.4. Spondylitis
13.19.5. Arthritis Mutilans
13.20. U.K. Psoriatic Arthritis Therapeutics Market Forecast, by Distribution Channel
13.20.1. Hospital Pharmacies
13.20.2. Online Pharmacies
13.20.3. Retail Pharmacies
13.21. U.K. Psoriatic Arthritis Therapeutics Market Forecast, by Route of Administration
13.21.1. Topical
13.21.2. Oral
13.21.3. Injectable
13.22. France Psoriatic Arthritis Therapeutics Market Forecast, by Drug Class
13.22.1. Nonsteroidal anti-inflammatory drug (NSAID)
13.22.2. Disease-modifying antirheumatic drug (DMARD)
13.22.3. Biologic drug
13.22.4. Enzyme inhibitor
13.22.5. Interleukin Inhibitors
13.22.6. Others
13.23. France Psoriatic Arthritis Therapeutics Market Forecast, by Disease Type
13.23.1. Asymmetric Psoriatic Arthritis
13.23.2. Symmetric Psoriatic Arthritis
13.23.3. Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis
13.23.4. Spondylitis
13.23.5. Arthritis Mutilans
13.24. France Psoriatic Arthritis Therapeutics Market Forecast, by Distribution Channel
13.24.1. Hospital Pharmacies
13.24.2. Online Pharmacies
13.24.3. Retail Pharmacies
13.25. France Psoriatic Arthritis Therapeutics Market Forecast, by Route of Administration
13.25.1. Topical
13.25.2. Oral
13.25.3. Injectable
13.26. Italy Psoriatic Arthritis Therapeutics Market Forecast, by Drug Class
13.26.1. Nonsteroidal anti-inflammatory drug (NSAID)
13.26.2. Disease-modifying antirheumatic drug (DMARD)
13.26.3. Biologic drug
13.26.4. Enzyme inhibitor
13.26.5. Interleukin Inhibitors
13.26.6. Others
13.27. Italy Psoriatic Arthritis Therapeutics Market Forecast, by Disease Type
13.27.1. Asymmetric Psoriatic Arthritis
13.27.2. Symmetric Psoriatic Arthritis
13.27.3. Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis
13.27.4. Spondylitis
13.27.5. Arthritis Mutilans
13.28. Italy Psoriatic Arthritis Therapeutics Market Forecast, by Distribution Channel
13.28.1. Hospital Pharmacies
13.28.2. Online Pharmacies
13.28.3. Retail Pharmacies
13.29. Italy Psoriatic Arthritis Therapeutics Market Forecast, by Route of Administration
13.29.1. Topical
13.29.2. Oral
13.29.3. Injectable
13.30. Spain Psoriatic Arthritis Therapeutics Market Forecast, by Drug Class
13.30.1. Nonsteroidal anti-inflammatory drug (NSAID)
13.30.2. Disease-modifying antirheumatic drug (DMARD)
13.30.3. Biologic drug
13.30.4. Enzyme inhibitor
13.30.5. Interleukin Inhibitors
13.30.6. Others
13.31. Spain Psoriatic Arthritis Therapeutics Market Forecast, by Disease Type
13.31.1. Asymmetric Psoriatic Arthritis
13.31.2. Symmetric Psoriatic Arthritis
13.31.3. Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis
13.31.4. Spondylitis
13.31.5. Arthritis Mutilans
13.32. Spain Psoriatic Arthritis Therapeutics Market Forecast, by Distribution Channel
13.32.1. Hospital Pharmacies
13.32.2. Online Pharmacies
13.32.3. Retail Pharmacies
13.33. Spain Psoriatic Arthritis Therapeutics Market Forecast, by Route of Administration
13.33.1. Topical
13.33.2. Oral
13.33.3. Injectable
13.34. Rest of Europe Psoriatic Arthritis Therapeutics Market Forecast, by Drug Class
13.34.1. Nonsteroidal anti-inflammatory drug (NSAID)
13.34.2. Disease-modifying antirheumatic drug (DMARD)
13.34.3. Biologic drug
13.34.4. Enzyme inhibitor
13.34.5. Interleukin Inhibitors
13.34.6. Others
13.35. Rest of Europe Psoriatic Arthritis Therapeutics Market Forecast, by Disease Type
13.35.1. Asymmetric Psoriatic Arthritis
13.35.2. Symmetric Psoriatic Arthritis
13.35.3. Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis
13.35.4. Spondylitis
13.35.5. Arthritis Mutilans
13.36. Rest of Europe Psoriatic Arthritis Therapeutics Market Forecast, by Distribution Channel
13.36.1. Hospital Pharmacies
13.36.2. Online Pharmacies
13.36.3. Retail Pharmacies
13.37. Rest Of Europe Psoriatic Arthritis Therapeutics Market Forecast, by Route of Administration
13.37.1. Topical
13.37.2. Oral
13.37.3. Injectable
13.38. Europe Psoriatic Arthritis Therapeutics Market Attractiveness Analysis
13.38.1. By Drug Class
13.38.2. By Disease Type
13.38.3. By Distribution Channel
13.38.4. By Route of Administration
13.39. PEST Analysis
13.40. Key Trends
13.41. Key Developments

14. Asia Pacific Psoriatic Arthritis Therapeutics Market Analysis
14.1. Key Findings
14.2. Asia Pacific Psoriatic Arthritis Therapeutics Market Overview
14.3. Asia Pacific Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Drug Class
14.4. Asia Pacific Psoriatic Arthritis Therapeutics Market Forecast, by Drug Class
14.4.1. Nonsteroidal anti-inflammatory drug (NSAID)
14.4.2. Disease-modifying antirheumatic drug (DMARD)
14.4.3. Biologic drug
14.4.4. Enzyme inhibitor
14.4.5. Interleukin Inhibitors
14.4.6. Others
14.5. Asia Pacific Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Disease Type
14.6. Asia Pacific Psoriatic Arthritis Therapeutics Market Forecast, by Disease Type
14.6.1. Asymmetric Psoriatic Arthritis
14.6.2. Symmetric Psoriatic Arthritis
14.6.3. Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis
14.6.4. Spondylitis
14.6.5. Arthritis Mutilans
14.7. Asia Pacific Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Distribution Channel
14.8. Asia Pacific Psoriatic Arthritis Therapeutics Market Forecast, by Distribution Channel
14.8.1. Hospital Pharmacies
14.8.2. Online Pharmacies
14.8.3. Retail Pharmacies
14.9. Asia Pacific Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Route of Administration
14.10. Asia Pacific Psoriatic Arthritis Therapeutics Market Forecast, by Route of Administration
14.10.1. Topical
14.10.2. Oral
14.10.3. Injectable
14.11. Asia Pacific Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Country
14.12. Asia Pacific Psoriatic Arthritis Therapeutics Market Forecast, by Country
14.12.1. China
14.12.2. India
14.12.3. Japan
14.12.4. ASEAN
14.12.5. Rest of Asia Pacific
14.13. Asia Pacific Psoriatic Arthritis Therapeutics Market Analysis, by Country
14.14. China Psoriatic Arthritis Therapeutics Market Forecast, by Drug Class
14.14.1. Nonsteroidal anti-inflammatory drug (NSAID)
14.14.2. Disease-modifying antirheumatic drug (DMARD)
14.14.3. Biologic drug
14.14.4. Enzyme inhibitor
14.14.5. Interleukin Inhibitors
14.14.6. Others
14.15. China Psoriatic Arthritis Therapeutics Market Forecast, by Disease Type
14.15.1. Asymmetric Psoriatic Arthritis
14.15.2. Symmetric Psoriatic Arthritis
14.15.3. Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis
14.15.4. Spondylitis
14.15.5. Arthritis Mutilans
14.16. China Psoriatic Arthritis Therapeutics Market Forecast, by Distribution Channel
14.16.1. Hospital Pharmacies
14.16.2. Online Pharmacies
14.16.3. Retail Pharmacies
14.17. China Psoriatic Arthritis Therapeutics Market Forecast, by Route of Administration
14.17.1. Topical
14.17.2. Oral
14.17.3. Injectable
14.18. India Psoriatic Arthritis Therapeutics Market Forecast, by Drug Class
14.18.1. Nonsteroidal anti-inflammatory drug (NSAID)
14.18.2. Disease-modifying antirheumatic drug (DMARD)
14.18.3. Biologic drug
14.18.4. Enzyme inhibitor
14.18.5. Interleukin Inhibitors
14.18.6. Others
14.19. India Psoriatic Arthritis Therapeutics Market Forecast, by Disease Type
14.19.1. Asymmetric Psoriatic Arthritis
14.19.2. Symmetric Psoriatic Arthritis
14.19.3. Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis
14.19.4. Spondylitis
14.19.5. Arthritis Mutilans
14.20. India Psoriatic Arthritis Therapeutics Market Forecast, by Distribution Channel
14.20.1. Hospital Pharmacies
14.20.2. Online Pharmacies
14.20.3. Retail Pharmacies
14.21. India Psoriatic Arthritis Therapeutics Market Forecast, by Route of Administration
14.21.1. Topical
14.21.2. Oral
14.21.3. Injectable
14.22. Japan Psoriatic Arthritis Therapeutics Market Forecast, by Drug Class
14.22.1. Nonsteroidal anti-inflammatory drug (NSAID)
14.22.2. Disease-modifying antirheumatic drug (DMARD)
14.22.3. Biologic drug
14.22.4. Enzyme inhibitor
14.22.5. Interleukin Inhibitors
14.22.6. Others
14.23. Japan Psoriatic Arthritis Therapeutics Market Forecast, by Disease Type
14.23.1. Asymmetric Psoriatic Arthritis
14.23.2. Symmetric Psoriatic Arthritis
14.23.3. Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis
14.23.4. Spondylitis
14.23.5. Arthritis Mutilans
14.24. Japan Psoriatic Arthritis Therapeutics Market Forecast, by Distribution Channel
14.24.1. Hospital Pharmacies
14.24.2. Online Pharmacies
14.24.3. Retail Pharmacies
14.25. Japan Psoriatic Arthritis Therapeutics Market Forecast, by Route of Administration
14.25.1. Topical
14.25.2. Oral
14.25.3. Injectable
14.26. ASEAN Psoriatic Arthritis Therapeutics Market Forecast, by Drug Class
14.26.1. Nonsteroidal anti-inflammatory drug (NSAID)
14.26.2. Disease-modifying antirheumatic drug (DMARD)
14.26.3. Biologic drug
14.26.4. Enzyme inhibitor
14.26.5. Interleukin Inhibitors
14.26.6. Others
14.27. ASEAN Psoriatic Arthritis Therapeutics Market Forecast, by Disease Type
14.27.1. Asymmetric Psoriatic Arthritis
14.27.2. Symmetric Psoriatic Arthritis
14.27.3. Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis
14.27.4. Spondylitis
14.27.5. Arthritis Mutilans
14.28. ASEAN Psoriatic Arthritis Therapeutics Market Forecast, by Distribution Channel
14.28.1. Hospital Pharmacies
14.28.2. Online Pharmacies
14.28.3. Retail Pharmacies
14.29. ASEAN Psoriatic Arthritis Therapeutics Market Forecast, by Route of Administration
14.29.1. Topical
14.29.2. Oral
14.29.3. Injectable
14.30. Rest of Asia Pacific Psoriatic Arthritis Therapeutics Market Forecast, by Drug Class
14.30.1. Nonsteroidal anti-inflammatory drug (NSAID)
14.30.2. Disease-modifying antirheumatic drug (DMARD)
14.30.3. Biologic drug
14.30.4. Enzyme inhibitor
14.30.5. Interleukin Inhibitors
14.30.6. Others
14.31. Rest of Asia Pacific Psoriatic Arthritis Therapeutics Market Forecast, by Disease Type
14.31.1. Asymmetric Psoriatic Arthritis
14.31.2. Symmetric Psoriatic Arthritis
14.31.3. Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis
14.31.4. Spondylitis
14.31.5. Arthritis Mutilans
14.32. Rest of Asia Pacific Psoriatic Arthritis Therapeutics Market Forecast, by Distribution Channel
14.32.1. Hospital Pharmacies
14.32.2. Online Pharmacies
14.32.3. Retail Pharmacies
14.33. Rest of Asia Pacific Psoriatic Arthritis Therapeutics Market Forecast, by Route of Administration
14.33.1. Topical
14.33.2. Oral
14.33.3. Injectable
14.34. Asia Pacific Psoriatic Arthritis Therapeutics Market Attractiveness Analysis
14.34.1. By Drug Class
14.34.2. By Disease Type
14.34.3. By Distribution Channel
14.34.4. By Route of Administration
14.35. PEST Analysis
14.36. Key Trends
14.37. Key Developments

15. Middle East & Africa Psoriatic Arthritis Therapeutics Market Analysis
15.1. Key Findings
15.2. Middle East & Africa Psoriatic Arthritis Therapeutics Market Overview
15.3. Middle East & Africa Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Drug Class
15.4. Middle East & Africa Psoriatic Arthritis Therapeutics Market Forecast, by Drug Class
15.4.1. Nonsteroidal anti-inflammatory drug (NSAID)
15.4.2. Disease-modifying antirheumatic drug (DMARD)
15.4.3. Biologic drug
15.4.4. Enzyme inhibitor
15.4.5. Interleukin Inhibitors
15.4.6. Others
15.5. Middle East & Africa Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Disease Type
15.6. Middle East & Africa Psoriatic Arthritis Therapeutics Market Forecast, by Disease Type
15.6.1. Asymmetric Psoriatic Arthritis
15.6.2. Symmetric Psoriatic Arthritis
15.6.3. Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis
15.6.4. Spondylitis
15.6.5. Arthritis Mutilans
15.7. Middle East & Africa Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Distribution Channel
15.8. Middle East & Africa Psoriatic Arthritis Therapeutics Market Forecast, by Distribution Channel
15.8.1. Hospital Pharmacies
15.8.2. Online Pharmacies
15.8.3. Retail Pharmacies
15.9. Middle East & Africa Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Route of Administration
15.10. Middle East & Africa Psoriatic Arthritis Therapeutics Market Forecast, by Route of Administration
15.10.1. Topical
15.10.2. Oral
15.10.3. Injectable
15.11. Middle East & Africa Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Country
15.12. Middle East & Africa Psoriatic Arthritis Therapeutics Market Forecast, by Country
15.12.1. GCC
15.12.2. South Africa
15.12.3. Rest of Middle East & Africa
15.13. Middle East & Africa Psoriatic Arthritis Therapeutics Market Analysis, by Country
15.14. GCC Psoriatic Arthritis Therapeutics Market Forecast, by Drug Class
15.14.1. Nonsteroidal anti-inflammatory drug (NSAID)
15.14.2. Disease-modifying antirheumatic drug (DMARD)
15.14.3. Biologic drug
15.14.4. Enzyme inhibitor
15.14.5. Interleukin Inhibitors
15.14.6. Others
15.15. GCC Psoriatic Arthritis Therapeutics Market Forecast, by Disease Type
15.15.1. Asymmetric Psoriatic Arthritis
15.15.2. Symmetric Psoriatic Arthritis
15.15.3. Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis
15.15.4. Spondylitis
15.15.5. Arthritis Mutilans
15.16. GCC Psoriatic Arthritis Therapeutics Market Forecast, by Distribution Channel
15.16.1. Hospital Pharmacies
15.16.2. Online Pharmacies
15.16.3. Retail Pharmacies
15.17. GCC Psoriatic Arthritis Therapeutics Market Forecast, by Route of Administration
15.17.1. Topical
15.17.2. Oral
15.17.3. Injectable
15.18. South Africa Psoriatic Arthritis Therapeutics Market Forecast, by Drug Class
15.18.1. Nonsteroidal anti-inflammatory drug (NSAID)
15.18.2. Disease-modifying antirheumatic drug (DMARD)
15.18.3. Biologic drug
15.18.4. Enzyme inhibitor
15.18.5. Interleukin Inhibitors
15.18.6. Others
15.19. South Africa Psoriatic Arthritis Therapeutics Market Forecast, by Disease Type
15.19.1. Asymmetric Psoriatic Arthritis
15.19.2. Symmetric Psoriatic Arthritis
15.19.3. Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis
15.19.4. Spondylitis
15.19.5. Arthritis Mutilans
15.20. South Africa Psoriatic Arthritis Therapeutics Market Forecast, by Distribution Channel
15.20.1. Hospital Pharmacies
15.20.2. Online Pharmacies
15.20.3. Retail Pharmacies
15.21. South Africa Psoriatic Arthritis Therapeutics Market Forecast, by Route of Administration
15.21.1. Topical
15.21.2. Oral
15.21.3. Injectable
15.22. Rest of Middle East & Africa Psoriatic Arthritis Therapeutics Market Forecast, by Drug Class
15.22.1. Nonsteroidal anti-inflammatory drug (NSAID)
15.22.2. Disease-modifying antirheumatic drug (DMARD)
15.22.3. Biologic drug
15.22.4. Enzyme inhibitor
15.22.5. Interleukin Inhibitors
15.22.6. Others
15.23. Rest of Middle East & Africa Psoriatic Arthritis Therapeutics Market Forecast, by Disease Type
15.23.1. Asymmetric Psoriatic Arthritis
15.23.2. Symmetric Psoriatic Arthritis
15.23.3. Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis
15.23.4. Spondylitis
15.23.5. Arthritis Mutilans
15.24. Rest of Middle East & Africa Psoriatic Arthritis Therapeutics Market Forecast, by Distribution Channel
15.24.1. Hospital Pharmacies
15.24.2. Online Pharmacies
15.24.3. Retail Pharmacies
15.25. Rest of Middle East & Africa Psoriatic Arthritis Therapeutics Market Forecast, by Route of Administration
15.25.1. Topical
15.25.2. Oral
15.25.3. Injectable
15.26. Middle East & Africa Psoriatic Arthritis Therapeutics Market Attractiveness Analysis
15.26.1. By Drug Class
15.26.2. By Disease Type
15.26.3. By Distribution Channel
15.26.4. By Route of Administration
15.27. PEST Analysis
15.28. Key Trends
15.29. Key Developments

16. South America Psoriatic Arthritis Therapeutics Market Analysis
16.1. Key Findings
16.2. South America Psoriatic Arthritis Therapeutics Market Overview
16.3. South America Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Drug Class
16.4. South America Psoriatic Arthritis Therapeutics Market Forecast, by Drug Class
16.4.1. Nonsteroidal anti-inflammatory drug (NSAID)
16.4.2. Disease-modifying antirheumatic drug (DMARD)
16.4.3. Biologic drug
16.4.4. Enzyme inhibitor
16.4.5. Interleukin Inhibitors
16.4.6. Others
16.5. South America Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Disease Type
16.6. South America Psoriatic Arthritis Therapeutics Market Forecast, by Disease Type
16.6.1. Asymmetric Psoriatic Arthritis
16.6.2. Symmetric Psoriatic Arthritis
16.6.3. Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis
16.6.4. Spondylitis
16.6.5. Arthritis Mutilans
16.7. South America Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Distribution Channel
16.8. South America Psoriatic Arthritis Therapeutics Market Forecast, by Distribution Channel
16.8.1. Hospital Pharmacies
16.8.2. Online Pharmacies
16.8.3. Retail Pharmacies
16.9. South America Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Route of Administration
16.10. South America Psoriatic Arthritis Therapeutics Market Forecast, by Route of Administration
16.10.1. Topical
16.10.2. Oral
16.10.3. Injectable
16.11. South America Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Country
16.12. South America Psoriatic Arthritis Therapeutics Market Forecast, by Country
16.12.1. Brazil
16.12.2. Mexico
16.12.3. Rest of South America
16.13. South America Psoriatic Arthritis Therapeutics Market Analysis, by Country
16.14. Brazil Psoriatic Arthritis Therapeutics Market Forecast, by Drug Class
16.14.1. Nonsteroidal anti-inflammatory drug (NSAID)
16.14.2. Disease-modifying antirheumatic drug (DMARD)
16.14.3. Biologic drug
16.14.4. Enzyme inhibitor
16.14.5. Interleukin Inhibitors
16.14.6. Others
16.15. Brazil Psoriatic Arthritis Therapeutics Market Forecast, by Disease Type
16.15.1. Asymmetric Psoriatic Arthritis
16.15.2. Symmetric Psoriatic Arthritis
16.15.3. Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis
16.15.4. Spondylitis
16.15.5. Arthritis Mutilans
16.16. Brazil Psoriatic Arthritis Therapeutics Market Forecast, by Distribution Channel
16.16.1. Hospital Pharmacies
16.16.2. Online Pharmacies
16.16.3. Retail Pharmacies
16.17. Brazil Psoriatic Arthritis Therapeutics Market Forecast, by Route of Administration
16.17.1. Topical
16.17.2. Oral
16.17.3. Injectable
16.18. Mexico Psoriatic Arthritis Therapeutics Market Forecast, by Drug Class
16.18.1. Nonsteroidal anti-inflammatory drug (NSAID)
16.18.2. Disease-modifying antirheumatic drug (DMARD)
16.18.3. Biologic drug
16.18.4. Enzyme inhibitor
16.18.5. Interleukin Inhibitors
16.18.6. Others
16.19. Mexico Psoriatic Arthritis Therapeutics Market Forecast, by Disease Type
16.19.1. Asymmetric Psoriatic Arthritis
16.19.2. Symmetric Psoriatic Arthritis
16.19.3. Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis
16.19.4. Spondylitis
16.19.5. Arthritis Mutilans
16.20. Mexico Psoriatic Arthritis Therapeutics Market Forecast, by Distribution Channel
16.20.1. Hospital Pharmacies
16.20.2. Online Pharmacies
16.20.3. Retail Pharmacies
16.21. Mexico Psoriatic Arthritis Therapeutics Market Forecast, by Route of Administration
16.21.1. Topical
16.21.2. Oral
16.21.3. Injectable
16.22. Rest of South America Psoriatic Arthritis Therapeutics Market Forecast, by Drug Class
16.22.1. Nonsteroidal anti-inflammatory drug (NSAID)
16.22.2. Disease-modifying antirheumatic drug (DMARD)
16.22.3. Biologic drug
16.22.4. Enzyme inhibitor
16.22.5. Interleukin Inhibitors
16.22.6. Others
16.23. Rest of South America Psoriatic Arthritis Therapeutics Market Forecast, by Disease Type
16.23.1. Asymmetric Psoriatic Arthritis
16.23.2. Symmetric Psoriatic Arthritis
16.23.3. Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis
16.23.4. Spondylitis
16.23.5. Arthritis Mutilans
16.24. Rest of South America Psoriatic Arthritis Therapeutics Market Forecast, by Distribution Channel
16.24.1. Hospital Pharmacies
16.24.2. Online Pharmacies
16.24.3. Retail Pharmacies
16.25. Rest of South America Psoriatic Arthritis Therapeutics Market Forecast, by Route of Administration
16.25.1. Topical
16.25.2. Oral
16.25.3. Injectable
16.26. South America Psoriatic Arthritis Therapeutics Market Attractiveness Analysis
16.26.1. By Drug Class
16.26.2. By Disease Type
16.26.3. By Distribution Channel
16.26.4. By Route of Administration
16.27. PEST Analysis
16.28. Key Trends
16.29. Key Developments

17. Company Profiles
17.1. Market Share Analysis, by Company
17.2. Competition Matrix
17.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment
17.2.2. New Product Launches and Product Enhancements
17.2.3. Market Consolidation
17.2.3.1. M&A by Regions, Investment and Applications
17.2.3.2. M&A Key Players, Forward Integration and Backward
Integration
17.3. Company Profiles: Key Players
17.3.1. Pfizer Inc
17.3.1.1. Company Overview
17.3.1.2. Financial Overview
17.3.1.3. Portfolio
17.3.1.4. Business Strategy
17.3.1.5. Recent Developments
17.3.1.6. Developing Footprint
17.3.2. Eisai Inc
17.3.3. UCB Biosciences Inc
17.3.4. Sanofi
17.3.5. Otsuka Pharmaceutical
17.3.6. Sumitomo Dainippon Pharma Co
17.3.7. Johnson & Johnson
17.3.8. Celgene Corporation
17.3.9. AbbVie Inc.
17.3.10. Novartis AG
17.3.11. Janssen Biotech
17.3.12. Eli Lilly and Company
17.3.13. Biogen Inc.
17.3.14. Bristol-Myers Squibb Company
17.3.15. Abbott Laboratories
17.3.16. Amgen Inc.
17.3.17. AstraZeneca
17.3.18. Merck & Co

18. Primary Key Insights
  • INQUIRE BEFORE BUYING